Clinical trials: Glaucoma Therapy
Optic Neuropathy, Glaucoma
Hyperbaric Oxygen Therapy for Optic Neuropathies
The purpose of the study is to evaluate the neuroprotective efficacy of hyperbaric oxygen for the treatment in patients with optic neuropathy.
- Trial name
- HBOT (NCT06128720)
- Testing
- Hyperbaric Oxygen
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Stanford University
Open-angle Glaucoma, Ocular Hypertension
Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®
The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering effect of Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) dosed twice daily (BID) when added to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®) in…
- Trial name
- NCT02730871
- Testing
- Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide/brimonidine vehicle, Travoprost 0.004%/timolol 0.5% solution
- Where
- United States
- Volunteers
- 173 people
- Sponsor
- Alcon Research
Chronic Obstructive Pulmonary Disease, Glaucoma, Angle-Closure
Effect of Tiotropium on Eye Findings in the Treatment of Chronic Obstructive Pulmonary Disease
This study aimed to examine the effect of Tiotropium, which is used in the treatment of COPD, on eye symptoms.The study was conducted prospectively. Patients were examined in three groups.
- Trial name
- NCT06525051
- Testing
- Tiotropium
- Where
- Turkey (Türkiye)
- Volunteers
- 108 people
- Sponsor
- Giresun University
Open-Angle Glaucoma, Ocular Hypertension
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
The purpose of the study is to evaluate the safety and effectiveness of an investigational glaucoma therapy in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00293800
- Testing
- Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution (XALATAN), Timolol 0.5% Ophthalmic Solution
- Volunteers
- 173 people
- Sponsor
- Alcon Research
Complications of Treatment, Progression
Comparison of Subconjuctival Versus Topical Bevacizumab as Adjunct Therapy to Trabeculectomy
Bevacizumab is an anti vascular endothelial growth factor(anti-VEGF) substance that is known to reduce neovascularization and fibrovascular proliferation in inflammatory conditions, including post-operative inflammation.
- Trial name
- NCT01425112
- Testing
- Phacoemulsification
- Volunteers
- 180 people
- Sponsor
- Sudhalkar Eye Hospital
Glaucoma
Safety of Topical Insulin Drops for Open-angle Glaucoma
Glaucoma, a leading cause of irreversible blindness worldwide, is characterized by a permanent loss of retinal ganglion cells (RGCs), a group of central nervous system (CNS) neurons that convey visual information from the retina…
- Trial name
- NCT04118920
- Testing
- Topical insulin (4 units), Topical insulin (20 units), Artificial tears
- Where
- Canada
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Open-angle Glaucoma, OAG
A Study to Evaluate Adverse Events and Change in Disease Activity With the XEN45 Glaucoma Treatment System Implantation In Adult Participants With Open-Angle Glaucoma in China
Glaucoma is the second most common cause of blindness in the world, second only to cataracts. The purpose of this study is to assess adverse events (AEs) and changes in disease activity in participants with open-angle glaucoma…
- Trial name
- NCT05821855
- Testing
- XEN45 Glaucoma Treatment System, Trabeculectomy
- Where
- 13 sites in China
- Volunteers
- 120 people
- Sponsor
- AbbVie
Open Angle Glaucoma or Ocular Hypertension
OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects
It is a phase III, multi-center, randomized, single-blind (to evaluator), parallel, and positive-controlled clinical trial evaluating the efficacy and safety of OPC-1085EL in the treatment of primary open angle glaucoma or ocular…
- Trial name
- NCT05583474
- Testing
- OPC-1085EL, 0.005% Latanoprost
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Otsuka Beijing Research Institute
Glaucoma
Satisfaction With XEN Gel Stent Versus Trabeculectomy for the Treatment of Glaucoma
This is a prospective, observational, non-interventional study of patients scheduled to receive surgical intervention either via XEN or trabeculectomy for open-angle glaucoma.
- Trial name
- XENPRO (NCT03852810)
- Where
- 10 sites in Canada, Germany and 1 more
- Volunteers
- 28 people
- Sponsor
- Allergan
Primary Open-Angle Glaucoma, Optic Nerve Injury
A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy
This is a randomized, double-masked, placebo-controlled Phase II clinical trial. The primary objective is to explore the efficacy of G01 Eye Drops in the treatment of optic nerve injury associated with open-angle glaucoma…
- Trial name
- NCT07777861
- Testing
- G01 Eye Drops 100μg/ml, G01 Eye Drops 200μg/ml
- Where
- 9 sites in China
- Volunteers
- 90 people
- Sponsor
- Qingdao WanMing BioCell Pharmaceutics Co.,Ltd.
Glaucoma, Ocular Hypertension
Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy
The purpose of this study was to evaluate the safety and efficacy of adding AZARGA® as a single agent to prostaglandin monotherapy in patients with either ocular hypertension or primary open-angle glaucoma.
- Trial name
- NCT01263444
- Testing
- Brinzolamide 1% / timolol 0.5% Fixed Combination, Habitual prostaglandin monotherapy
- Volunteers
- 47 people
- Sponsor
- Alcon Research
Glaucoma
Development and Implementation of an Educational Program to Enhance Adherence to Glaucoma Treatment
This study evaluates the addition of an educational intervention program in order to improve medication adherence in glaucoma patients.
- Trial name
- NCT04245163
- Testing
- Educational program
- Where
- Cyprus
- Volunteers
- 40 people
- Sponsor
- Cyprus University of Technology
Growth Hormone Treatment, Glaucoma
Is Recombinant Growth Hormone Therapy Associated With Increased Intraoccular Pressure?
Recombinant growth hormone is a common therapy in the pediatric population. A number of associated side effects have been described.
- Trial name
- NCT00867971
- Testing
- Measuring intraoccular pressure
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Assaf-Harofeh Medical Center
Glaucoma, Glaucoma, Open-Angle
XEN45 in the Treatment of Chinese Patients With Primary Open-angle Glaucoma
Glaucoma is the second most common blindness disease in the world, second only to cataracts. The current treatment of glaucoma is mainly to reduce intraocular pressure.At present, two commonly used surgical methods are…
- Conditions
- Glaucoma, Glaucoma, Open-Angle, Surgery
- Trial name
- NCT05130554
- Testing
- XEN45 gel stent implantation
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Open Angle Glaucoma
Surgical Treatment of Refractory Open Angle Glaucoma
The primary objective of this study is to evaluate the safety, efficacy, and performance of the Suprachoroidal Dissection Instrument in creating a fistula between Schlemm's canal and the suprachoroidal space in refractory, open…
- Trial name
- NCT01212861
- Testing
- Suprachoroidal Dissection Instrument (SDI)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- iScience Interventional Corporation
Glaucomatous Neuropathy
Study of Glaucoma Treatment With Food Additives
The purpose of this study is to determine if certain food additives are effective in the treatment of glaucoma, improving and reversing the progress of the disease.
- Trial name
- NCT00196677
- Testing
- Vitamins, minerals and medical herbs
- Where
- Israel
- Volunteers
- 25 people
- Sponsor
- Future Products Management
Glaucoma, Primary Open Angle (POAG), Ocular Hypertension
Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure
To determine the predictive factors of a positive response to latanoprost 0.005% / timolol 0.5% fixed combination (defined as a 10% IOP reduction from baseline), after 12 weeks of treatment (age, sex, ethnic origin, patient's…
- Trial name
- PREDICOM (NCT00230763)
- Testing
- GSS questionnaire, IOP, LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION
- Where
- 102 sites in France
- Volunteers
- 396 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Open-angle Glaucoma, Ocular Hypertension
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00287521
- Testing
- AL-37807 Ophthalmic Suspension, 1.0%, Latanoprost, 0.005% (Xalatan), AL-37807 Vehicle
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Alcon Research
Ocular Hypertension, Primary Open Angle Glaucoma of Both Eyes
Is the Reduction in IOP After Treatment of 180 Degrees Equivalent to Treatment of 360 Degrees With SLT?
The study is a prospective randomised controlled intervention comparing the intraocular pressure outcomes following Selective Laser Trabeculoplasty (SLT) treatment of 180 degrees SLT compared to 360 degrees in treatment naive…
- Conditions
- Ocular Hypertension, Primary Open Angle Glaucoma of Both Eyes, Intraocular Pressure
- Trial name
- SLT (NCT03529591)
- Testing
- Selective laser trabeculoplasty (SLT), Selective laser trabeculoplasty
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Western University, Canada
Primary Open Angle Glaucoma of Both Eyes
Comparative Study of Dorzotimol Eye Drops, 20 mg/mL + 5 mg/mL Versus Cosopt® Eye Drops, 20 mg/mL + 5 mg/mL
The goal of this study is to compare efficacy and safety of Dorzotimol eye drops, 20 mg/mL + 5 mg/mL manufactured by JADRAN-GALENSKI LABORATORIJ d.d.
- Trial name
- NCT05973318
- Testing
- Dorzotimol eye drops, 20 mg/mL + 5 mg/mL, Cosopt eye drops, 20 mg/mL + 5 mg/mL
- Where
- Russia
- Volunteers
- 110 people
- Sponsor
- Jadran Galenski laboratorij d.d.